{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T10:48:00Z","timestamp":1787482080608,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12325-019-01166-3","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:43:06Z","timestamp":1576507386000},"page":"457-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Cost-Effectiveness Analysis of Glecaprevir\/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis\u00a0C in Japan"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-9466","authenticated-orcid":false,"given":"Isao","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri Sanchez","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchin","family":"Virabhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cammy","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"1 Suppl","key":"1166_CR1","first-page":"S65","volume":"15","author":"GG Liu","year":"2012","unstructured":"Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis\u00a0C: evidence from a national survey in Japan. Value Health. 2012;15(1 Suppl):S65\u201371.","journal-title":"Value Health"},{"issue":"3","key":"1166_CR2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","volume":"9","author":"H Bennett","year":"2015","unstructured":"Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis\u00a0C virus infection in China Japan South Korea and Taiwan. Hepatol Int. 2015;9(3):378\u201390.","journal-title":"Hepatol Int"},{"issue":"1 Suppl","key":"1166_CR3","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis\u00a0C virus infection. J Hepatol. 2014;61(1 Suppl):S45\u201357.","journal-title":"J Hepatol"},{"issue":"1","key":"1166_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5005\/jp-journals-10018-1166","volume":"6","author":"H Yatsuhashi","year":"2016","unstructured":"Yatsuhashi H. Past, present, and future of Viral Hepatitis\u00a0C in Japan. Euroasian J Hepatogastroenterol. 2016;6(1):49\u201351.","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"Suppl 19","key":"1166_CR5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00535-008-2251-0","volume":"44","author":"T Umemura","year":"2009","unstructured":"Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl 19):102\u20137.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1166_CR6","doi-asserted-by":"crossref","first-page":"e0199188","DOI":"10.1371\/journal.pone.0199188","volume":"13","author":"K Matsumoto","year":"2018","unstructured":"Matsumoto K, Wu Y, Kitazawa T, Fujita S, Seto K, Hasegawa T. Cost of illness of hepatocellular carcinoma in Japan: a time trend and future projections. PLoS One. 2018;13(6):e0199188.","journal-title":"PLoS One"},{"issue":"1","key":"1166_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000367727","volume":"4","author":"M Kudo","year":"2015","unstructured":"Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4(1):39\u201350.","journal-title":"Liver Cancer"},{"issue":"4","key":"1166_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324525","volume":"54","author":"J Tanaka","year":"2011","unstructured":"Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis\u00a0C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54(4):185\u201395.","journal-title":"Intervirology"},{"issue":"12","key":"1166_CR9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/jmv.25267","volume":"90","author":"K Morio","year":"2018","unstructured":"Morio K, Imamura M, Kawakami Y, et al. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis\u00a0C. J Med Virol. 2018;90(12):1834\u201340.","journal-title":"J Med Virol"},{"issue":"Suppl S1","key":"1166_CR10","first-page":"59","volume":"44","author":"Y Asahina","year":"2014","unstructured":"Asahina Y, Hayashi N, Izumi N, et al. JSH guidelines for the management of hepatitis\u00a0C virus infection: a 2014 update for genotype 1. Hepatol Res. 2014;44(Suppl S1):59\u201370.","journal-title":"Hepatol Res"},{"issue":"12","key":"1166_CR11","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jvh.12967","volume":"25","author":"K Hayashi","year":"2018","unstructured":"Hayashi K, Ishigami M, Ishizu Y, et al. Late relapse of hepatitis\u00a0C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat. 2018;25(12):1446\u201351.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1166_CR12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","volume":"38","author":"K Kozbial","year":"2018","unstructured":"Kozbial K, Moser S, Al-Zoairy R, et al. Follow-up of sustained virological responders with hepatitis\u00a0C and advanced liver disease after interferon\/ribavirin-free treatment. Liver Int. 2018;38(6):1028\u201335.","journal-title":"Liver Int"},{"issue":"8","key":"1166_CR13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jvh.12886","volume":"25","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis\u00a0C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat. 2018;25(8):945\u201351.","journal-title":"J Viral Hepat"},{"key":"1166_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Maviret (G\/P) Product Insert [In Japanese only]. http:\/\/www.info.pmda.go.jp\/go\/pack\/6250113F1021_1_04\/. Accessed 11 Sept 2019."},{"key":"1166_CR15","unstructured":"Pharmaceutical Technology. AbbVie\u2019s Maviret receives Japanese MHLW approval to treat HCV. 2017. https:\/\/www.pharmaceutical-technology.com\/news\/newsabbvies-maviret-receives-japanese-mhlw-approval-to-treat-hcv-5935729\/. Accessed 11 Sept 2019."},{"issue":"12","key":"1166_CR16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1080\/13696998.2016.1206908","volume":"19","author":"S Virabhak","year":"2016","unstructured":"Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of direct-acting antiviral regimen ombitasvir\/paritaprevir\/ritonavir in treatment-naive and treatment-experienced patients infected with chronic hepatitis\u00a0C virus genotype 1b in Japan. J Med Econ. 2016;19(12):1144\u201356.","journal-title":"J Med Econ"},{"key":"1166_CR17","unstructured":"Ishida H, Yotsuyanagi H. Examination of the cost-effectiveness of the standard of care for chronic HCV treatment [In Japanese only]. Research on medical economic evaluation of various measures related to viral liver disease: MHLW, 2014. Report No.: 20133004B: Cat No.: 20133004B007-20133004B0010: Pages: 127\u2013192. https:\/\/mhlw-grants.niph.go.jp\/niph\/search\/NIDD00.do?resrchNum=201333004B. Accessed 3 Nov 2019."},{"issue":"17","key":"1166_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15170","volume":"15","author":"D Hartwell","year":"2011","unstructured":"Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis\u00a0C in patients eligible for shortened treatment re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):1\u2013210 (i\u2013xii).","journal-title":"Health Technol Assess"},{"issue":"2","key":"1166_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis\u00a0C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology"},{"issue":"2","key":"1166_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0266462309090229","volume":"25","author":"M Grishchenko","year":"2009","unstructured":"Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis\u00a0C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25(2):171\u201380.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"1166_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","volume":"156","author":"S Liu","year":"2012","unstructured":"Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis\u00a0CA cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279\u201390.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1166_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL","year":"2017","unstructured":"EASL. Recommendations on treatment of hepatitis\u00a0C 2016. J Hepatol. 2017;66(1):153\u201394.","journal-title":"J Hepatol"},{"issue":"3","key":"1166_CR23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD-IDSA","year":"2015","unstructured":"AASLD-IDSA. Hepatitis\u00a0C guidance: AASLD-IDSA recommendations for testing managing and treating adults infected with hepatitis\u00a0C virus. Hepatology. 2015;62(3):932\u201354.","journal-title":"Hepatology"},{"issue":"1","key":"1166_CR24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","volume":"60","author":"F Kanwal","year":"2014","unstructured":"Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology. 2014;60(1):98\u2013105.","journal-title":"Hepatology"},{"issue":"2","key":"1166_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","volume":"174","author":"J McCombs","year":"2014","unstructured":"McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis\u00a0C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174(2):204\u201312.","journal-title":"JAMA Intern Med."},{"issue":"5","key":"1166_CR26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/03007995.2017.1288613","volume":"33","author":"A Goolsby Hunter","year":"2017","unstructured":"Goolsby Hunter A, Rosenblatt L, Patel C, Blauer-Peterson C, Anduze-Faris B. Clinical characteristics healthcare costs and resource utilization in hepatitis\u00a0C vary by genotype. Curr Med Res Opin. 2017;33(5):829\u201336.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1166_CR27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1440-1746.2011.06871.x","volume":"27","author":"D Maruoka","year":"2012","unstructured":"Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis\u00a0C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27(2):291\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Supplement C","key":"1166_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vhri.2014.04.005","volume":"3","author":"P McEwan","year":"2014","unstructured":"McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis\u00a0C genotype 1b. Value Health Reg Issues. 2014;3(Supplement C):136\u201345.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"1166_CR29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463\u201372.","journal-title":"Gastroenterology"},{"issue":"6","key":"1166_CR30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","volume":"43","author":"A Sangiovanni","year":"2006","unstructured":"Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis\u00a0C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303\u201310.","journal-title":"Hepatology"},{"issue":"6","key":"1166_CR31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/lt.500040604","volume":"4","author":"JP Achkar","year":"1998","unstructured":"Achkar JP, Araya V, Baron RL, Marsh JW, Dvorchik I, Rakela J. Undetected hepatocellular carcinoma: clinical features and outcome after liver transplantation. Liver transplantat Surg. 1998;4(6):477\u201382.","journal-title":"Liver transplantat Surg"},{"key":"1166_CR32","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/gut.52.suppl_3.iii1","volume":"52","author":"SD Ryder","year":"2003","unstructured":"Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:iii1\u20138.","journal-title":"Gut"},{"issue":"11","key":"1166_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","volume":"11","author":"J Shepherd","year":"2007","unstructured":"Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis\u00a0C: a systematic review and economic evaluation. Health Technol Assess. 2007;11(11):1\u2013205iii.","journal-title":"Health Technol Assess"},{"key":"1166_CR34","unstructured":"Mochida S, et al. Post-marketing observational study on glecaprevir\/pibrentasvir in chronic hepatitis\u00a0C patients without cirrhosis or with compensated cirrhosis: an interim report. In: The 55th Annual Meeting of Japan Society of Hepatology 2019."},{"key":"1166_CR35","unstructured":"AbbVie GK. CERTAIN-1 study results [In Japanese only]. Summary documents on Maviret. Section 2.7.3.2.1.1. pp 29\u201341.\u00a0http:\/\/www.pmda.go.jp\/drugs\/2017\/P20171013002\/112130000_22900AMX00973000_K102_1.pdf."},{"key":"1166_CR36","unstructured":"AbbVie GK. CERTAIN-2 study results [In Japanese only]. Summary documents on Maviret. Section 2.7.3.2.1.2. pp 41\u201348.\u00a0http:\/\/www.pmda.go.jp\/drugs\/2017\/P20171013002\/112130000_22900AMX00973000_K102_1.pdf."},{"key":"1166_CR37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis\u00a0C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557\u201365.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1166_CR38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00535-016-1245-6","volume":"52","author":"J Toyota","year":"2017","unstructured":"Toyota J, Karino Y, Suzuki F, et al. Daclatasvir\/asunaprevir\/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol. 2017;52(3):385\u201395.","journal-title":"J Gastroenterol"},{"issue":"4","key":"1166_CR39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00535-016-1285-y","volume":"52","author":"H Kumada","year":"2017","unstructured":"Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study. J Gastroenterol. 2017;52(4):520\u201333.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1166_CR40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis\u00a0C: an open-label randomised phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1166_CR41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in japanese patients with chronic genotype 2 hepatitis\u00a0C virus infection. Hepatology. 2018;67(2):505\u201313.","journal-title":"Hepatology"},{"key":"1166_CR42","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience severe renal impairment or genotype 3 infection. J Gastroenterol. 2018;53:566\u201375.","journal-title":"J Gastroenterol"},{"issue":"9","key":"1166_CR43","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/liv.13685","volume":"38","author":"Y Asahina","year":"2018","unstructured":"Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir-sofosbuvir for treating japanese patients with chronic hepatitis\u00a0C virus genotype 2 infection. Liver Int. 2018;38(9):1552\u201361.","journal-title":"Liver Int"},{"key":"1166_CR44","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Harvoni (SOF\/LDV) Product Insert [In Japanese only]. http:\/\/www.info.pmda.go.jp\/go\/pack\/6250107F1026_1_12\/. Accessed 11 Sept 2019."},{"key":"1166_CR45","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Grazyna (GZR) Product Insert [In Japanese only]. http:\/\/www.info.pmda.go.jp\/go\/pack\/6250043F1024_1_04\/. Accessed 11 Sept 2019."},{"key":"1166_CR46","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Erelsa (EBR) Product Insert [In Japanese only]. http:\/\/www.info.pmda.go.jp\/go\/pack\/6250044F1029_1_03\/. Accessed 11 Sept 2019."},{"key":"1166_CR47","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Ximency (DCV\/ASV\/BCV) Product Insert [In Japanese only]. http:\/\/www.info.pmda.go.jp\/go\/pack\/6250112F1027_1_03\/. Accessed 11 Sept 2019."},{"issue":"21","key":"1166_CR48","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993\u20132001.","journal-title":"N Engl J Med"},{"key":"1166_CR49","volume-title":"Elbasvir-grazoprevir for treating chronic hepatitis\u00a0C [ID842]. Technology appraisal guidance [TA413]","author":"NICE","year":"2016","unstructured":"NICE. Elbasvir-grazoprevir for treating chronic hepatitis\u00a0C [ID842]. Technology appraisal guidance [TA413]. London: National Institute for Health and Care Excellence; 2016."},{"key":"1166_CR50","volume-title":"Ledipasvir-sofosbuvir for treating chronic hepatitis\u00a0C [ID742]","author":"NICE","year":"2015","unstructured":"NICE. Ledipasvir-sofosbuvir for treating chronic hepatitis\u00a0C [ID742]. London: National Institute for Health and Care Excellence; 2015."},{"key":"1166_CR51","unstructured":"Fukuda T, et al. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Health and Labour Science Research Grants Strategic Integrated Scientific Research Project. 2019."},{"key":"1166_CR52","unstructured":"Japanese National Health Insurance drug price list [In Japanese only]. 2019. https:\/\/www.mhlw.go.jp\/topics\/2018\/04\/dl\/tp20190403-01_01.pdf. Accessed 11 Sept 2019."},{"issue":"6","key":"1166_CR53","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835\u201342.","journal-title":"Value Health"},{"issue":"1","key":"1166_CR54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9\u201317.","journal-title":"Value Health"},{"key":"1166_CR55","first-page":"625","volume":"62","author":"T Fukuda","year":"2013","unstructured":"Fukuda T, Shiroiwa T, Ikeda S, et al. Guideline for economic evaluation of healthcare technologies in Japan. J Natl Inst Public Health. 2013;62:625\u201340.","journal-title":"J Natl Inst Public Health"},{"key":"1166_CR56","unstructured":"Board of Governors of the Federal Reserve System. Historical Rates for the Japanese Yen. In: Foreign Exchange Rates - H.10. Washington DC. 2019. https:\/\/www.federalreserve.gov\/releases\/h10\/Hist\/dat00_ja.htm. Accessed 3 June 2019."},{"key":"1166_CR57","first-page":"40","volume":"4","author":"FBIA Kristensen","year":"2018","unstructured":"Kristensen FBIA, Neumann PJ, Goldman DP. Challenges and best practices for the Japan health technology assessment pilot program. Value Outcomes Spotlight. 2018;4:40\u20131.","journal-title":"Value Outcomes Spotlight"},{"issue":"10","key":"1166_CR58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/13696998.2016.1189920","volume":"19","author":"SJ Johnson","year":"2016","unstructured":"Johnson SJ, Parise H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis\u00a0C virus infection. J Med Econ. 2016;19(10):983\u201394.","journal-title":"J Med Econ"},{"key":"1166_CR59","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","edition":"3"},{"key":"1166_CR60","unstructured":"York Health Economics Consortium. Cost-effectiveness frontier. York. 2016. http:\/\/www.yhec.co.uk\/glossary\/cost-effectiveness-frontier\/. Accessed 11 Sept 2019."},{"issue":"4","key":"1166_CR61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X03255922","volume":"23","author":"AH Briggs","year":"2003","unstructured":"Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Mak. 2003;23(4):341\u201350.","journal-title":"Med Decis Mak"},{"key":"1166_CR62","volume-title":"Glecaprevir\u2013pibrentasvir for treating chronic hepatitis\u00a0C technology appraisal guidance [TA499]","author":"NICE","year":"2018","unstructured":"NICE. Glecaprevir\u2013pibrentasvir for treating chronic hepatitis\u00a0C technology appraisal guidance [TA499]. London: National Institute for Health and Care Excellence; 2018."},{"key":"1166_CR63","volume-title":"Ombitasvir\u2013paritaprevir\u2013ritonavir with or without dasabuvir for treating chronic hepatitis\u00a0C technology appraisal guidance [TA365]","author":"NICE","year":"2015","unstructured":"NICE. Ombitasvir\u2013paritaprevir\u2013ritonavir with or without dasabuvir for treating chronic hepatitis\u00a0C technology appraisal guidance [TA365]. London: National Institute for Health and Care Excellence; 2015."},{"issue":"4 Pt 1","key":"1166_CR64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","volume":"34","author":"AJ Freeman","year":"2001","unstructured":"Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis\u00a0C virus infection. Hepatology. 2001;34(4 Pt 1):809\u201316.","journal-title":"Hepatology"},{"key":"1166_CR65","volume-title":"Pegylated interferon combined with ribavirin for chronic hepatitis\u00a0C virus infection: an economic evaluation [technology report no 82]","author":"B Brady","year":"2007","unstructured":"Brady B, Siebert U, Sroczynski G, et al. Pegylated interferon combined with ribavirin for chronic hepatitis\u00a0C virus infection: an economic evaluation [technology report no 82]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007."},{"issue":"2","key":"1166_CR66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis\u00a0C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology"},{"issue":"1","key":"1166_CR67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","volume":"20","author":"HJ Alter","year":"2000","unstructured":"Alter HJ, Seeff LB. Recovery persistence and sequelae in hepatitis\u00a0C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17\u201335.","journal-title":"Semin Liver Dis"},{"key":"1166_CR68","unstructured":"AbbVie Inc. Application for inclusion of Maviret (glecaprevir\/pibrentasvir) on the WHO Model List of Essential Medicines (EML). Geneva, Switzerland. 2019. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/22\/applications\/s6.4.4.2_glecprevir-pibrentasvir.pdf. Accessed 3 Nov 2019."},{"issue":"6","key":"1166_CR69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hepr.13328","volume":"49","author":"E Ogawa","year":"2019","unstructured":"Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis\u00a0C genotype 1 or 2 infection: results from a multicenter real-world cohort study. Hepatol Res. 2019;49(6):617\u201326.","journal-title":"Hepatol Res"},{"issue":"8","key":"1166_CR70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","volume":"118","author":"S-J Hsu","year":"2019","unstructured":"Hsu S-J, Chiu M-C, Fang Y-J, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis\u00a0C. J Formos Med Assoc. 2019;118(8):1187\u201392.","journal-title":"J Formos Med Assoc"},{"key":"1166_CR71","unstructured":"Suka M, Igarashi A, Kitazawa T, Yoda T. Development of the fundamental model for HCV [In Japanese only]. Research on medical economic evaluation of various measures related to viral liver disease: MHLW, 2014. Report No.: 20133004B: Cat No.: 20133004B0004-20133004B0005: Pages: 76\u201395. https:\/\/mhlw-grants.niph.go.jp\/niph\/search\/NIDD00.do?resrchNum=2013330-04B. Accessed 3 Nov 2019."},{"key":"1166_CR72","unstructured":"Ministry of Health Labour and Welfare. Abridged life tables for Japan 2017. In: Statistics and Information Department. Minister\u2019s Secretariat Government of Japan. 2017."},{"issue":"27","key":"1166_CR73","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608\u201317.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01166-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T18:14:27Z","timestamp":1722190467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01166-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}